Share-based Payment Arrangement, Expense of Akari Therapeutics Plc from 31 Dec 2010 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Akari Therapeutics Plc quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 30 Sep 2025.
  • Akari Therapeutics Plc Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $685,000, a 176% increase year-over-year.
  • Akari Therapeutics Plc Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $3,675,000, a 156% increase year-over-year.
  • Akari Therapeutics Plc annual Share-based Payment Arrangement, Expense for 2024 was $2,245,000, a 95% increase from 2023.
  • Akari Therapeutics Plc annual Share-based Payment Arrangement, Expense for 2023 was $1,150,000, a 105% increase from 2022.
  • Akari Therapeutics Plc annual Share-based Payment Arrangement, Expense for 2022 was $560,060, a 78% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Akari Therapeutics Plc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $3,675,000 $685,000 +$437,000 +176% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $3,238,000 $719,000 +$274,000 +62% 01 Apr 2025 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 $2,964,000 $1,015,000 +$719,000 +243% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $2,245,000 $1,256,000 +$809,437 +181% 01 Oct 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
Q3 2024 $1,435,563 $248,000 -$57,000 -19% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $1,492,563 $445,000 +$311,563 +233% 01 Apr 2024 30 Jun 2024 10-Q 13 Aug 2025 2025 Q2
Q1 2024 $1,181,000 $296,000 +$31,000 +12% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $1,150,000 $446,563 01 Oct 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
Q3 2023 $305,000 01 Jul 2023 30 Sep 2023 10-Q 19 Nov 2024 2024 Q3
Q2 2023 $133,437 01 Apr 2023 30 Jun 2023 8-K 06 Sep 2024
Q1 2023 $265,000 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1

Akari Therapeutics Plc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,245,000 +$1,095,000 +95% 01 Jan 2024 31 Dec 2024 10-K 15 Apr 2025 2024 FY
2023 $1,150,000 +$589,940 +105% 01 Jan 2023 31 Dec 2023 10-K 15 Apr 2025 2024 FY
2022 $560,060 +$245,410 +78% 01 Jan 2022 31 Dec 2022 8-K 06 Sep 2024
2021 $314,650 -$10,873 -3.3% 01 Jan 2021 31 Dec 2021 20-F 01 May 2023 2022 FY
2020 $325,523 01 Jan 2020 31 Dec 2020 20-F 01 May 2023 2022 FY
2014 $410,000 +$336,000 +454% 01 Jan 2014 31 Dec 2014 10-K 11 Feb 2015 2014 FY
2013 $74,000 -$311,000 -81% 01 Jan 2013 31 Dec 2013 10-K 11 Feb 2015 2014 FY
2012 $385,000 +$365,000 +1825% 01 Jan 2012 31 Dec 2012 10-K 11 Feb 2015 2014 FY
2011 $20,000 +$115,000 01 Jan 2011 31 Dec 2011 20-F 24 Mar 2014 2013 FY
2010 $95,000 01 Jan 2010 31 Dec 2010 20-F/A 19 Apr 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.